These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28977112)

  • 1. PSA screening for prostate cancer.
    Sadi MV
    Rev Assoc Med Bras (1992); 2017 Aug; 63(8):722-725. PubMed ID: 28977112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
    Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline prostate-specific antigen testing at a young age.
    Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
    Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indirect consequences of PSA testing for prostate cancer screening].
    Naïmi R; Senglet M; De Gorski A; Kherad O
    Rev Med Suisse; 2020 Feb; 16(680):275-277. PubMed ID: 32022494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: a review of common underwriting problems, Part 1.
    Richie RC; Swanson JO
    J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for prostate cancer with PSA testing: current status and future directions.
    Croswell JM; Kramer BS; Crawford ED
    Oncology (Williston Park); 2011 May; 25(6):452-60, 463. PubMed ID: 21717898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PSA screening].
    Spek A; Szabados B; Roosen A; Stief C
    Dtsch Med Wochenschr; 2015 Sep; 140(19):1435-7. PubMed ID: 26402179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
    BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA in screening for prostate cancer: more good than harm or more harm than good?
    Duffy MJ
    Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostate cancer screening: Reasons of controversy].
    Delporte G; Villers A; Penel N
    Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
    Joshi SS; Filson CP
    Cancer; 2020 Feb; 126(4):694-696. PubMed ID: 31794066
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen screening: pro.
    Loeb S; Catalona WJ
    Curr Opin Urol; 2010 May; 20(3):185-8. PubMed ID: 20224413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
    Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
    Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.